Gemina Laboratories Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLABF research report →
About the company
Gemina Laboratories Ltd. is a Canadian biotechnology enterprise primarily focused on the investigation, creation, and commercialization of in vitro diagnostic solutions. The firm's innovation extends to developing unique surface functionalization chemistries specifically designed for the identification of pathogens and various biological markers.
- CEO
- Robert Crandall Greene
- IPO
- 2022
- Employees
- 6
- HQ
- Burnaby, BC, CA
Price Chart
- Market Cap
- $3.83M
- P/E
- -1.54
- P/S
- 422.34
- P/B
- -0.89
- EV/EBITDA
- -1.74
- Div Yield
- 0.00%
- Gross Margin
- -496.49%
- Op Margin
- -26104.51%
- Net Margin
- -26928.44%
- ROE
- 62.39%
- ROIC
- 57.93%
- Revenue
- $21.50K · 0.00%
- Net Income
- $-2,342,251 · 42.50%
- EPS
- $-0.03 · 44.18%
- Op Income
- $-2,237,705
- FCF YoY
- 60.12%
- 52W High
- $0.62
- 52W Low
- $0.04
- 50D MA
- $0.05
- 200D MA
- $0.12
- Beta
- -0.07
- Avg Volume
- 110.78K
Get TickerSpark's AI analysis on GLABF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GLABF coverage
Recent articles, reports, and earnings notes.
No research on GLABF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GLABF report →Similar companies
Peers in the same neighborhood.